Rothschild, S; Amrein, Michael; Riether, Carsten; Gautschi, O; Schuster, N; Li, Q; Savic, S; Schneider, M; Biaggi, C; Bubendorf, L; Brutsche, M; Zippelius, A; Zander, T; Betticher, D; Früh, M; Stahel, R; Cathomas, R; Rauch, Daniel; Pless, M; Ochsenbein, Adrian; ... (October 2017). CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09). Journal of thoracic oncology, 12(11S2), S1864-S1865. Elsevier
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
pdf.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (438kB) |
Item Type: |
Conference or Workshop Item (Poster) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Tumor-Immunologie |
UniBE Contributor: |
Amrein, Michael Alex, Riether, Carsten, Rauch, Daniel, Ochsenbein, Adrian |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1556-1380 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Nicole Corminboeuf |
Date Deposited: |
27 Mar 2018 09:38 |
Last Modified: |
02 Mar 2023 23:30 |
BORIS DOI: |
10.7892/boris.111402 |
URI: |
https://boris.unibe.ch/id/eprint/111402 |
Actions (login required)
 |
Edit item |